AbstractCOP‐1, a synthetic basic random amino acid copolymer, is effective in suppression of experimental allergic encephalomyelitis in guinea pigs, rabbits, mice, rhesus monkeys and baboons, and of the exacerbating‐remitting type of multiple sclerosis in humans. COP‐1 is cross‐reactive at the monoclonal antibody level with the basic protein of the myelin sheath of the brain (BP), and the suppressive effect may be related to this immunological cross‐reaction. Indeed, competition for the major histocompatibility complex (MHC) class II antigen, between BP and COP‐1, may be one explanation for its beneficial effect in the disease. This polymeric drug, COP‐1, may, therefore, be considered also an immunomodulatory vaccine, and may serve as a prototype to vaccines against autoimmune diseases.
Read full abstract